LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC
Titel:
LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC
Auteur:
Cho, B.C. Rodriguez-Abreu, D. Hussein, M. Cobo, M. Patel, A. Secen, N. Gerstner, G. Kim, D-W. Lee, Y-G. Su, W-C. Huang, E. Patil, N. Huang, M. Zhang, Z. Wen, X. Mendus, D. Hoang, T. Meng, R. Johnson, M.L.